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Abstract
The endocervical mucosa is believed to be a primary site of HIV transmission. However, to date there is little known about the
distribution of the HIV co-receptor CCR5 and the HIV-binding C-type lectin receptors, including Langerin, dendritic cell (DC)-
specific intercellular adhesion molecule-grabbing non-integrin (DC-SIGN) and mannose receptor (MR) at this site. We therefore
characterized the expression of these molecules in the endocervix of HIV seronegative women by computerized image
analysis. Endocervical tissue biopsies were collected from women (n=6) undergoing hysterectomy. All study individuals were
diagnosed with benign and non-inflammatory diseases. CCR5+ CD4+ CD3+ T cells were found within or adjacent to the
endocervical epithelium. The C-type lectin Langerin was expressed by intraepithelial CD1a+ CD4+ and CD11c+ CD4+
Langerhans cells, whereas DC-SIGN+ MR+ CD11c myeloid dendritic cells and MR+ CD68+ macrophages were localized in the
submucosa of the endocervix. The previously defined immune effector cells including CD8+, CD56+, CD19+ and IgD+ cells
were also found in the submucosa as well as occasional CD123+ BDCA-2+ plasmacytoid dendritic cells. Understanding the
spatial distribution of potential HIV target cells and immune effector cells in relation to the endocervical canal forms a basis for
deciphering the routes of HIV transmission events in humans as well as designing HIV-inhibiting compounds.
Citation: Hirbod T, Kaldensjo ¨ T, Broliden K (2011) In Situ Distribution of HIV-Binding CCR5 and C-Type Lectin Receptors in the Human Endocervical Mucosa. PLoS
ONE 6(9): e25551. doi:10.1371/journal.pone.0025551
Editor: Xia Jin, University of Rochester, United States of America
Received June 28, 2011; Accepted September 7, 2011; Published September 30, 2011
Copyright:  2011 Hirbod et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by grants from Vetenskapsra ˚det, SIDA and Stiftelsen La ¨kare mot AIDS. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: tove.kaldensjo@ki.se
Introduction
The predominant route of human immunodeficiency virus (HIV)
infection in women is across the genital mucosa through
heterosexual transmission. However, the relative susceptibility of
individual mucosal sites in the female genital tract to primary HIV
transmission is unknown. The influence of hormones and sexually
transmitted infections as well as the exposure to microbial antigens
in the seminal plasma make the endocervical mucosa a complex
immunologicalenvironment.Themechanicalbarrierformedbythe
single-layered columnar epithelium of the endocervix is, even when
intact, less robust for preventing the invasion of pathogens than the
multi-layeredsquamousepitheliumofthevaginaandectocervix[1].
Although the mucus in the endocervical canal provides a medium
for innate immune molecules and forms a physical barrier to
invading pathogens [2], it is never totally impermeable. In an ex
vivo organ culture model, both cell-bound HIV and virions were
temporarily trapped by the cervical mucus but could also reach the
epithelial surface and penetrate to mucosal target cells [3].
In vivo studies in rhesus macaques [4,5] and human vaginal
explant studies [6] suggest that HIV target cells in the genital tract
mucosa are CD4+ T cells, Langerhans cells (LCs), interstitial
dendritic cells (DCs) and macrophages. In addition to conventional
bindingtothemain receptorCD4and the co-receptor CCR5;DCs,
LCs and macrophages can bind HIV through other receptor
pathways including C-type lectin receptors (CLRs) [7]. Little is
known about the presence and distribution of HIV-binding CLRs
such as the mannose receptor (MR) [8,9], the DC-specific
intercellular adhesion molecule-grabbing non-integrin (DC-SIGN)
[10] and Langerin [11] in the human endocervix. The physiological
role ofthese receptorswhen bound to HIVparticlesis dependenton
the location, timing and concentration of the inoculum as well as on
host inflammatory and hormonal factors. For example, HIV-
binding to DC-SIGN impairs DC maturation, weakens T cell
proliferation and mediates transmission of HIV to T cells [11]
whereasimmature LCsmayforma barrieragainstHIVinfectionby
efficiently capturingand degradingthe virus through Langerin [12].
Previous studies of HIV or simian immunodeficiency virus (SIV)
immune markers in the endocervical mucosa are limited and based
on either flow cytometry of enzyme-digested tissues or cytobrush-
obtained cervical specimens from humans [13,14,15], or immuno-
histochemical staining on tissue samples derived from rhesus
macaques [16] and humans [17,18,19]. However, the distribution
of CCR5+ CD4+ T cells or of CLR expressing antigen-presenting
cell subsets has not been described in human endocervical tissue.
This study was therefore designed to characterize and define these
HIV-binding receptors at the single cell level in the epithelial and
submucosal compartments of the human endocervix.
Materials and Methods
Study population and sample collection
Written informed consent was obtained from all study subjects,
and ethical approval was obtained from the Regional Ethical
Review Board in Stockholm. Endocervical tissue samples were
obtained from six women undergoing hysterectomy for non-
malignant, non-inflammatory indications (leiomyomata and ade-
nomyosis); mean age was 47.5 years (range 39–51 years). The
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e25551inclusion criteria were: HIV IgG seronegativity, no clinical
symptoms of sexually transmitted infections during the prior three
months and no use of hormonal therapy. The hysterectomy samples
were immediately transported on ice to the pathology department,
where a gynecological pathology specialist collected endocervical
tissue samples. Menstrual cycle stage was determined by endome-
trial dating. Two study subjects were in the proliferative phase, two
were in the secretory phase, and two had an inactive endometrium.
In situ detection of cellular markers by immunostaining
The endocervical tissue samples were snap frozen in liquid nitrogen
within 30 minutes of surgical removal. As previously described [20,21],
the cryopreserved tissue samples were sectioned to 8 mm, fixed in 2%
formaldehyde, blocked for endogenous biotin (Biotin/Avidin Blocking
Kit; Vector Laboratories, Burlingame, CA) and immunohistochemi-
cally stained. The following anti-human antibodies were used to detect
the immune markers of interest: goat anti-Langerin (clone#: AF2088
diluted 1:250), mouse anti-DC-SIGN (clone#: 120507 diluted 1:500),
goat anti-DLEC (BDCA-2 clone#: AF1376 diluted 1:25) (R&D
Systems, Minneapolis, MN), mouse anti-CD4 (clone#:S K 3d i l u t e d
1:10), mouse-anti CD3 (clone#:S K 7d i l u t e d1 : 1 0 ) ,m o u s ea n t i - C D 8
(clone#: SK1 diluted 1:10), mouse anti-CD56 (clone#:M Y 3 1d i l u t e d
1:500), mouse anti-CD19 (clone#: HIB19 diluted 1:500), mouse anti-
MR (clone#: 19.2 diluted 1:700), mouse anti-CD11c (clone#:B - l y 6
diluted 1:100), mouse anti-CD123 (clone#: 9F5 diluted 1:1000), mouse
anti-CD123 (clone#: 7G3 diluted 1:10) (BD Pharmingen, Franklin
Lakes, NJ), rat anti-CD4 (clone#: YNB46.1.8 diluted 1:100), mouse
anti-CD1a (clone#: NA/1/34-HLK diluted 1:500 ) (Serotec, Du ¨ssel-
dorf, Germany), mouse anti-CD68 (clone#: EBM11 diluted 1:200)
(DAKO, Stockholm, Sweden), goat anti-IgD (clone#: 2030-08 diluted
1:5000) (SouthernBiotech, Birmingham, AL) and mouse anti-CCR5
(clone#: MC-5 diluted 1:100) (kindly provided by Professor M. Mack
from the University Clinic of Regensburg, Germany). Thereafter
biotinylatedsecondaryantibodiesdiluted1:500wereadded;rabbitanti-
mouse,rabbitanti-goat(DAKO),goatanti-mouse(CaltagLaboratories,
Invitrogen, Life Technologies Corporation, Carlsbad, CA, USA) or
goat anti-rat (Vector laboratories). The staining reactions were
developed brown by using diaminobenzidine tetrahydrochloride
(DAB; Vector Laboratories), and nuclear counterstaining was per-
formed with hematoxylin. Digital images were transferred from a
DMR-X microscope (Leica, Wetzlar, Germany) into a computerized
image analysis system, Quantimet, Q 550 IW (Leica Imaging Systems,
Cambridge, UK). For one and double - fluorescent staining,
endocervical tissue sections were stained as described above except that
Alexa Flour 488 streptavidin (Invitrogen) or Alexa Flour 594 labeled
streptavidin (Invitrogen) were used to visualize the cells of interest.
Fluorescently labeled cells were evaluated using the Qwin 550
software and a filter-free spectral confocal microscope (Leica TCS
SP2 AOBS). Negative control staining consisted of irrelevant
mouse, rat or goat IgG (DAKo).
Quantitative analysis
Expression of the investigated markers was analyzed in
approximately 3610
6 mm
2 endocervical tissue per study individual
by using the computerized image analysis system, Quantimet, Q
550 IW (Leica) and Adobe Photoshop CS3 (Adobe Systems
Incorporated, San Jose, CA).
Results
Distribution of CD4+ and antigen-presenting cells in the
human endocervix
CD4+ cells were organized within or in close proximity to the
endocervical columnar epithelium in all study subjects (median:
0.012 positive cells/100 mm
2 [range: 0.006–0.027 positive cells/
100 mm
2]). Representative results are presented in Figure 1.
CD11c+ cells (defined here as mucosal myeloid DCs) followed a
similar distribution pattern and frequency as CD4+ cells (median:
0.013 positive cells/100 mm
2 [range: 0.007–0.024 positive cells/
100 mm
2]) (Figure 1). CD68+ cells (defined here as macrophages)
were also present in both the intraepithelial and submucosal
compartments, but not in the clustered distribution noted for
CD4+ and CD11c+ cells (Figure 1). However, CD68+ cells were
the most frequent of all cellular markers investigated in this
endocervical tissue (median: 0.036 positive cells/100 mm
2 [range:
0.017–0.049 positive cells/100 mm
2]), whereas CD1a+ cells
(defined here as LCs), which were mainly located within the
epithelium, were the least abundant (median: 0.002 positive cells/
100 mm
2 [range: 0.0004–0.014 positive cells/100 mm
2]) (Figure 1).
CD123+ cells were present in low frequencies and solely in the
submucosal compartment (median: 0.007 positive cells/100 mm
2
[range: 0.003–0.011 positive cells/100 mm
2]) (Figure 1).
CD4 was expressed on 40–52% of endocervical CD3+ T cells,
but also on all detected CD1a+ and CD11c+ cells. Representative
results are presented in figure 2. Although all CD1a+ LCs were
CD11c+, merely 15% of CD11c+ cells expressed CD1a (Figure 2).
CD4 was also expressed on 8% of CD123+ cells (Figure 2). Since
CD123 is expressed by plasmacytoid DCs (pDCs) but may also be
expressed by additional cell types, a supplementary pDC-specific
marker, BDCA-2, was used. Only 17% of the CD123+ cells co-
expressed BDCA-2 and could thus accurately be defined as pDCs
(Figure 2). The CD123+BDCA-2+ cells expressed neither CD1a
nor CD11c (data not shown).
CLRs and CCR5 are expressed in the human endocervix
Langerin+ cells were scarce (median: 0.009 positive cells/
100 mm
2 [range: 0.004–0.015 positive cells/100 mm
2]) and mainly
located within the epithelium but also in the underlying submucosa.
Representative results are presented in figure 3. Langerin was
expressed on 45% of the CD11c+ cells, 4% of the CD4+ cells
(Figure 3) and all detected endocervical CD1a+ cells but not on
CD68+ cells (data not shown). MR was the most frequent CLR
detected (median: 0.05 positive cells/100 mm
2 [range: 0.013–0.08
positive cells/100 mm
2]). MR expressing cells were not detected in
the epithelium; however, the CLR was present in the underlying
submucosa as close as 30 mm from the epithelial surface (Figure 3).
ThedistributionofDC-SIGN+ cellswassimilartothatofMR+ cells
(as close as 50 mm from the epithelial surface) although less frequent
(median: 0.009 positive cells/100 mm
2 [range: 0.005–0.028 positive
cells/100 mm
2]) (Figure 3). Moreover, in some study individuals
certain parts of the columnar epithelium expressed a weak
unspecific DC-SIGN staining. Both MR and DC-SIGN were
frequently expressed on CD68+ cells (97% and 35%, respectively)
and on CD11c+ cells (86% and 38%, respectively) (Figure 3), but
not on CD1a+ cells (data not shown). CD1a+ cells did not express
CCR5, whereas CCR5+CD4+ cells and CCR5+CD11c+ cells were
apparent within and adjacent to the endocervical epithelium
(Figure 3). Neither of the investigated CLRs was present on
CD123+BDCA-2+ cells (data not shown).
Distribution of immune effector cells in the human
endocervix
Effector cells with potential cytotoxic activity or antibody-
dependent functional activity include CD8+ cells (here defined as
cytotoxic T cells), CD56+ cells (defined as a subset of natural killer
cells) and CD19+ cells (defined as B cells), respectively. The
distribution of CD8+, CD56+, CD19+ and IgD+ cells was
characterized (Figure 4), but the cells were not further quantified.
HIV-Binding Receptors in Human Endocervix
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cells were located within or close to the endocervical epithelium.
CD56+ cells were also detected both in the epithelium and the
submucosa. In contrast, CD19+ cells as well as IgD producing cells
were only seen in the submucosa (as close as 120 mm and 55 mmt o
the epithelial surface, respectively).
Discussion
Here, the presence of the potential HIV-binding receptors
CCR5, Langerin, DC-SIGN and MR was visualized and their
intraepithelial and/or submucosal localization in the human
endocervix was demonstrated at the single cell level. These studies
thereby complement previous data on the distribution of HIV
receptors in human ectocervix [22] and endometrium [23]. Our
present data from non-inflamed endocervical tissue indicate that
Langerin+ cells are located in the single-cell layered epithelium in
direct contact with the endocervical canal and could thus be
accessible for HIV-binding and transmission. Furthermore,
CCR5+ cells were seen in the endocervical epithelium and
submucosa, corresponding to results from the human endometri-
um [23] and vaginal submucosa of rhesus macaques [24]. DC-
SIGN+ and MR+ cells, although absent from the epithelial layer,
were superficially located in the submucosa where other cell
populations relevant for effector immune functions were found.
The relative contributions of human endocervical CD4+ T cells
and antigen-presenting cells to initial HIV transmission are not
clear, but experimental studies in the SIV-macaque model show
focal infection of CD4+ T cells in the endocervical mucosa within
a few days following intravaginal inoculation of SIV [25,26].
Although intraepithelial CCR5+ CD4+ CD3+ T cells, CD1a+ and
Langerin+ cells have previously been detected in cytobrush-
obtained human cervical samples [14,27], their in situ distribution
has hitherto not been defined. The intraepithelial Langerin+
Figure 1. Distribution of CD4+ and antigen-presenting cells in the human endocervix. a: CD4+, Scale bar: 100 mm. Box depicts zoomed
area proximal to columnar epithelium. b: CD11c+, Scale bar: 100 mm. Box depicts zoomed area proximal to columnar epithelium. c: CD68+, Scale bar:
100 mm. Box depicts zoomed area proximal to columnar epithelium. d: CD1a+, Scale bar: 100 mm. Box depicts zoomed area proximal to columnar
epithelium. e: CD123+, Scale bar: 50 mm.
doi:10.1371/journal.pone.0025551.g001
HIV-Binding Receptors in Human Endocervix
PLoS ONE | www.plosone.org 3 September 2011 | Volume 6 | Issue 9 | e25551CD1a+ LCs were rare, but their location in the single-cell layered
epithelium and their expression of Langerin and CD4 make them
likely targets for primary HIV transmission. However, the direct
sampling of viral particles by endocervical cells has not been
shown in vivo. The ano-genital columnar epithelium has been
proposed to lack LCs [28] and a previous study on human
endocervices found no CD1a+ cells [19]. However,intraepithelial
CD1a+ cells have been detected in endocervical tissue from rhesus
macaques [16] and our group recently discovered Langerin+
CD1a+ cells in the single-layer uterine epithelium [23]. The cause
of this discrepancy may be differing experimental procedures,
underlying differences in the tissue or amount of tissue
investigated. Furthermore, in contrast to previous findings in
tissues from the human vagina [6] and cervix [27], we did not
identify CD1a+ LCs that co-expressed CCR5.
Additional HIV target cells including DC-SIGN+ MR+
CD11c+ myeloid DCs and MR+ CD68+ macrophages were
disseminated within the endocervical submucosa. The compart-
mentalization of MR+ and DC-SIGN+ expressing cells to the
endocervical submucosa is similar to previous findings in human
skin [29], endometrium [23] and ectocervix [22]. In a recent
report using primary genital epithelial cells of cervical and
endometrial origin, exposure to the HIV envelope glycoprotein
was found to reduce the epithelial monolayer’s integrity by up-
regulation of inflammatory cytokines [30]. Thus, the underlying
submucosal cells may theoretically be accessible to HIV-infected
seminal fluid following sexual intercourse. Furthermore, the
integrin CD11c together with the b chain CD18 form the
complement receptor 4 (CR4 or CD11c/CD18). CR4 is expressed
on antigen presenting cells including DCs and macrophages.
Figure 2. CD4 expression is present on T cells and antigen-presenting cell subsets. a: CD4+ (red),CD3+ (green), CD4+CD3+ (yellow), I:
3 mm, Scale bar: 25 mm. b: CD4+ (red), CD1a+ (green), CD4+CD1a+ (yellow), I: 24 mm, Scale bar: 25 mm. c: CD4+ (red), CD11c+ (green), CD4+CD11c+
(yellow), Scale bar: 25 mm. d: CD11c+ (red), CD1a (green), CD11c+CD1a+ (yellow), Scale bar: 25 mm. e: CD123+ (red), CD4+ (green,) CD123+CD4+
(yellow), Scale bar: 25 mm. f: CD123+ (red), BDCA-2+ (green,) CD123+BDCA-2+ (yellow), Scale bar: 25 mm. Arrows indicate single positive cells;
arrowheads indicate double positive cells.
doi:10.1371/journal.pone.0025551.g002
HIV-Binding Receptors in Human Endocervix
PLoS ONE | www.plosone.org 4 September 2011 | Volume 6 | Issue 9 | e25551Complement opsonized HIV can infect immature DCs through
binding via complement receptor 3 (CR3) or CR4 and this has been
shown to enhance HIV infectivity in vitro [31]. Thus, the CD11c+
cellsinthisstudymaybind HIVbothvia theirCLRsaswellasCR4.
The endocervical mucosa is an immunologically active site
includingcellsforming both innateand adaptiveimmune responses.
A subpopulation of DCs, the BDCA-2+ CD123+ pDCs, forms an
interface between innate and adaptive immunity, and these cells
werefoundtobe solely located inthesubmucosa.To our knowledge
this is the first report on the presence of BDCA-2+ CD123+ pDCs
in a non-inflamed human endocervix, although the number of such
cells was very low. pDCs have been implicated as important players
in both immune control of recurrent HSV infection [32] and the
immune response following SIV exposure in the endocervix of
rhesus macaques [25], but their function in the human endocervix
remains to be established.
Among the additional leukocyte populations amenable to
interaction with HIV are natural killer cells [33] and DC-SIGN
Figure 3. HIV-binding CLRs and CCR5 are expressed in the human endocervix. a: Langerin+, Scale bar: 100 mm. b: CD11c+ (red), Langerin+ (green),
CD11c+ Langerin+ (yellow), Scale bar: 25 mm. c: CD4+ (red), Langerin+ (green), CD4+ Langerin+ (yellow), Scale bar: 25 mm. d: MR+, Scale bar: 100 mm. e: DC-
SIGN+, Scale bar: 100 mm. f: MR+ (red),CD68+ (green), MR+CD68+ (yellow), Scale bar: 25 mm. g: DC-SIGN+ (red), CD68+ (green), DC-SIGN+CD68+ (yellow), Scale
bar: 25 mm. h: MR+ (red), CD11c+ (green), MR+CD11c+ (yellow), Scale bar: 25 mm. i: DC-SIGN+ (red), CD11c+ (green), DC-SIGN+CD11c+ (yellow), Scale bar:
25 mm. j: CD1a+ (green), CCR5+ (red), Scale bar: 25 mm. k: CD4+ (green), CCR5+ (red), CD4+CCR5+ (yellow), Scale bar: 25 mm. l: CD11c+ (green), CCR5+ (red),
CD11c+CCR5+ (yellow), Scale bar: 100 mm. Arrows indicate single positive cells; arrowheads indicate double positive cells.
doi:10.1371/journal.pone.0025551.g003
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pathways for HIV-related immune events at different sites of the
female genital mucosa needs further exploration. Indeed, natural
killer cells express differing phenotypic markers throughout the
female genital tract [35], and the CD56 marker used in the present
study does not cover all these subtypes. Nevertheless, as reported
previously [19,36] also under non-inflammatory conditions,
several types of immune cells including CD8+, CD56+ and
CD19+ cells as well as antibody-producing cells were present and
located near the CD4, CCR5 and CLR-expressing cells.
The expression of HIV target cells and receptors is critically
dependent on the inflammatory status of the genital mucosa, as
suggested by a recent report that described the persistence of HIV-
receptor positive inflammatory cells in herpes-affected genital skin
evenlong afterclinicalhealing and clearanceofherpessimplexvirus
(HSV) antigen [37]. Furthermore, female sex hormone levels
including exogenous hormonal contraceptives affect the immune
response in the female genital tract [38,39,40]. For example, CCR5
expression on uterine epithelial cells increases during the prolifer-
ative phase [41], whereas it remains relatively stable throughout the
menstrual cycle in ectocervical epithelium [42]. Based on this and
other findings, a ‘‘window of vulnerability’’ has been proposed in an
interval of 7–10 days after ovulation during which susceptibility to
HIV transmission increases due to hormonally induced immune
suppression [43]. Hormone levels also influence localization of the
border between the ectocervix and the endocervix. During puberty,
pregnancy and hormonal contraceptive use, the endocervical
epithelium may be exposed to the vaginal lumen: a condition
called cervical ectopy [44]. When the integrity of the epithelial layer
has been disrupted through mechanical microabrasion after
intercourse or inflammatory conditions, cells in the submucosa of
females with ectopy may be directly exposed to virus-containing
seminal fluid. In fact, cervical ectopy has been associated with an
increased risk of HIV infection [45]. The study subjects in this
report represented three stages of the menstrual cycle, but the small
sizeof this study group precluded the usefulness of statistical analysis
of hormonal influence. However, the investigated markers were
observed in endocervices representing all menstrual cycle stages.
The single-layer columnar epithelium of the endocervix is
considered to make it a prime target site for sexual transmission of
HIV. The detection at the single cell level enabled us to visualize the
locations of the HIV-binding receptors in relation to one another, to
plot their proximity to corresponding immune cells and to measure the
distance of submucosal cells from the epithelial surface. An important
application of our findings is that many of the current microbicide
candidates are based on hindering the interaction of HIV with its
receptors including the CCR5 and CLR molecules. Consequently,
understanding susceptibility to HIV infection in non-inflamed human
endocervical tissue during the relatively common situation of low-risk
settings impacts the design of HIV receptor-blocking compounds.
Future studies should also include subjects at higher risk of HIV
infection such as those with inflammatory conditions and representa-
tives of other ethnic and geographical settings.
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